GlaxoSmithKline (NYSE: GSK) — Perfil da empresa, notícias e dados financeiros
GlaxoSmithKline is a global healthcare company specializing in innovative pharmaceuticals, vaccines, and consumer healthcare products.
GlaxoSmithKline
GlaxoSmithKline is a global biopharmaceutical company headquartered in London, United Kingdom, that focuses on the discovery, development, and manufacture of human prescription medicines and vaccines. The company operates across core therapeutic areas including respiratory, immunology and inflammation, oncology, HIV, and general infectious diseases. GlaxoSmithKline conducts advanced research and clinical trials through international R&D hubs and operates an extensive global supply chain to distribute pharmaceutical treatments and immunisation products. The business serves patients, healthcare professionals, and healthcare systems across North America, Europe, Asia-Pacific, and emerging international markets.
Resumo
Operações
Produtos e/ou serviços de GlaxoSmithKline
- Vaccines: Research, development, and international manufacturing of prophylactic vaccines protecting against respiratory syncytial virus, shingles, meningococcal disease, hepatitis, and rotavirus, supplied to national immunization programs and global public health agencies worldwide.
- HIV Treatments: Clinical development, manufacturing, and commercial delivery of antiretroviral therapies and long-acting injectable regimens for HIV treatment and pre-exposure prophylaxis, distributed across hospital networks and specialty pharmacy channels in global pharmaceutical markets.
- Respiratory, Immunology and Inflammation Therapies: Production and commercialization of targeted biologic treatments and inhaled maintenance medications for severe asthma, chronic obstructive pulmonary disease, eosinophilic disorders, and systemic lupus erythematosus distributed across key regional markets.
- Oncology Therapeutics: Development and commercial supply of targeted cancer treatments, including antibody-drug conjugates, immuno-oncology therapies, and PARP inhibitors for hematological malignancies, gynecologic cancers, and various solid tumor indications in global clinical settings.
- Infectious Disease Treatments: Research and production of antiviral therapies, novel oral anti-infectives, and targeted monoclonal antibodies addressing respiratory pathogens, complicated urinary tract infections, chronic hepatitis B, and antimicrobial-resistant bacterial infections.
- General Medicines: Manufacturing and distribution of established legacy prescription pharmaceuticals, including respiratory inhalers, oral antibiotics, cardiovascular treatments, and allergy medications supplied to pharmacies and healthcare institutions in emerging and mature global regions.
equipe executiva do GlaxoSmithKline
- Julie Belita BrownCFO & Executive Director
- Jesse L. GoodmanScientific & Medical Expert
- Luke Victor MielsCEO & Director
- Shobie RamakrishnanChief Digital & Technology Officer
- Tony WoodChief Scientific Officer and Head of R&D
- Constantin FestSenior VP & Head of Investor Relations
- James FordSenior VP and Group General Counsel of Legal & Compliance
- David Simon RedfernPresident of Corporate Development
- Roanne ParryChief People Officer
- Philip C. ThomsonPresident of Global Affairs
Últimas notícias sobre a GlaxoSmithKline
GSK reports £8.89 billion in third-quarter revenue.
United StatesFDA approves GSK’s Hibsago for chronic hepatitis B
United StatesHUTCHMED closes $1.3 billion GSK cancer drug licensing deal
United StatesFDA approves GSK’s Hibsago for chronic hepatitis B
United StatesHUTCHMED licenses cancer drug for $110 million
United StatesGSK posts $11.28 billion Q2 revenue and launches £1.9 billion savings drive
United States
Histórico de dividendos
Dividendos por ação pagos pela GlaxoSmithKline , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $1.8433 |
| FY2025 | — | — | — | $1.6750 |
| FY2024 | — | — | — | $1.5570 |
| FY2023 | — | — | — | $1.3890 |
| FY2022 | — | — | — | $1.6800 |
Principais indicadores financeiros
Resultados divulgados pela GlaxoSmithKline , em GBP.
- Cap. de mercado
- 103,3 bi
- Receita (TTM)
- 33,5 bi
- P/L
- 18.0
- LPA (diluído, TTM)
- 2.9
- Dividend yield
- 3.5%
- Margem de lucro
- 13.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 32,7 bi | 7,9 bi | 5,7 bi | |
| 31,4 bi | 4 bi | 2,6 bi | |
| 30,3 bi | 6,7 bi | 4,9 bi | |
| 29,3 bi | 6,4 bi | 15 bi |